Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

August

31

TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference

WESTMINSTER, Colo.–(BUSINESS WIRE)–Aug. 31, 2026– TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the...

6

TriSalus Life Sciences Reports Second Quarter 2026 Results

Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and...

4

TriSalus Life Sciences to Host Virtual Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease

Key opinion leader will join company management to discuss the unmet need and current...

13

TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance

Reports $11.6 million in revenue, up 57% year-over-year, reflecting strong liver embolization growth Investigator-published data show...

11

TriSalus Life Sciences to Participate in Upcoming Investor Conferences

WESTMINSTER, Colo.–(BUSINESS WIRE)–Nov. 11, 2025– TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the...

30

TriSalus Life Sciences Announces $22.0 Million Private Placement and Preliminary Q1 2025 Unaudited Financial Results

Funding Anticipated to Accelerate Applications Already in Use and New Additional Potential Applications Anticipated...

27

TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

DENVER–(BUSINESS WIRE)–Mar. 27, 2025– TriSalus Life Sciences Inc., (Nasdaq: TLSI), oncology focused medical technology business...

6

TriSalus Life Sciences® Announces Its Researchers Received Two JVIR Top Paper Awards for Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”

DENVER–(BUSINESS WIRE)–Mar. 6, 2025– TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life...

4

TriSalus Life Sciences Announces Key Appointments to Board of Directors

Healthcare industry veterans William Valle and Gary Gordon, MD add strategic expertise in medical devices,...

23

TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results

DENVER–(BUSINESS WIRE)–Jan. 23, 2025– TriSalus Life Sciences® Inc. (Nasdaq: TLSI), is announcing preliminary unaudited fourth quarter and...

14

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

– Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year...

11

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

DENVER–(BUSINESS WIRE)–Nov. 11, 2024– TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology...

Recent developments

News

August

31

TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference

August

6

TriSalus Life Sciences Reports Second Quarter 2026 Results

December

4

TriSalus Life Sciences to Host Virtual Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease

November

13

TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance

November

11

TriSalus Life Sciences to Participate in Upcoming Investor Conferences

April

30

TriSalus Life Sciences Announces $22.0 Million Private Placement and Preliminary Q1 2025 Unaudited Financial Results

March

27

TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

March

6

TriSalus Life Sciences® Announces Its Researchers Received Two JVIR Top Paper Awards for Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”

February

4

TriSalus Life Sciences Announces Key Appointments to Board of Directors

January

23

TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results

November

14

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

November

11

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer